Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04412616 · ClinicalTrials.gov registry record · Phase 1
ZZ06 in Adult Patients With Advanced Solid Tumor Malignancies
A Phase 1 study of Advanced EGFR Positive Solid Tumor, sponsored by Changchun Intellicrown Pharmaceutical Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 5
- Study locations
NCT04412616: Recruiting Phase 1 study of Advanced EGFR Positive Solid Tumor, sponsored by Changchun Intellicrown Pharmaceutical Co..
NCT04412616 is a Phase 1 study of Advanced EGFR Positive Solid Tumor that is actively recruiting participants, run by Changchun Intellicrown Pharmaceutical Co.. The registered enrollment target is 60 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04412616, a Phase 1 study of Advanced EGFR Positive Solid Tumor, is actively recruiting participants, sponsored by Changchun Intellicrown Pharmaceutical Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a Phase 1, Multicenter, Open-label study to assess the safety, tolerability and preliminary efficacy of ZZ06 in participants with all Adult Patients with Advanced EGFR-positive Solid Tumor Malignancies who are not able to have current standard anti-tumor therapies. The purpose of this study is to determine the maximum tolerated dose (MTD) , to characterise the safety, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of ZZ06 as a single agent in adult participants with advanced solid tumors.
Primary Outcome
Adverse events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events v5.0
Conditions Studied
Interventions
- BIOLOGICAL ZZ06
Study Locations (5)
Jilin
- Jilin Cancer Hospital - Changchun
- The first Bethune hospital of Jilin University - Changchun
California
- Cedars Sinai Medical Center - Los Angeles
Kansas
- Kansas University Cancer Center - Fairway
New York
- Montefiore Medical Center - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2020-09-01 |
| Est. Completion | 2026-07-06 |
| Phase | Phase 1 |
What NCT04412616 shows while recruiting
NCT04412616 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 1 condition, with Advanced EGFR Positive Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which ZZ06 is the first listed.
NCT04412616 lists 5 locations in 4 states (Jilin, California, Kansas).
Frequently Asked Questions
What is clinical trial NCT04412616 about?
NCT04412616 is a clinical study titled "ZZ06 in Adult Patients With Advanced Solid Tumor Malignancies". This is a Phase 1, Multicenter, Open-label study to assess the safety, tolerability and preliminary efficacy of ZZ06 in participants with all Adult Patients with Advanced EGFR-positive Solid Tumor Malignancies who are not able to have current standard anti-tumor therapies. The purpose of this study ...
What is the current status of trial NCT04412616?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2020-09-01. Estimated completion is 2026-07-06.
What conditions does trial NCT04412616 study?
This clinical trial studies the following conditions: Advanced EGFR Positive Solid Tumor.
What interventions are being tested in trial NCT04412616?
The interventions under investigation include: ZZ06 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04412616?
This trial is sponsored by Changchun Intellicrown Pharmaceutical Co., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04412616 being conducted?
This trial has 5 study locations across California, Kansas, New York, Jilin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04412616's enrollment target sits among peer trials
60 832nd of 2000 higher than 1,106 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI